All topical ophthalmic agents should be considered potentially potent systemically
Many Australians are prescribed topical ophthalmic medications for chronic conditions such as glaucoma, ocular inflammation, infection and allergy. Despite their overall safety, these agents have the potential to cause significant systemic side effects and to have serious interactions with oral medications. In many cases, these effects may go unreported by the patient or misdiagnosed by the medical community. There is a need for improved prescribing practices in both the ophthalmic and general medical communities, with increased awareness of the full range of therapeutic agents being taken by the patient. With the recent passage of legislation allowing optometrists prescribing rights under the Pharmaceutical Benefits Scheme (PBS) (National Health Amendment [Pharmaceutical Benefits] Act 2007 [Cwlth]), it is timely to remind all health care practitioners of the potential hazards of topical ophthalmic medications.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Korte JM, Kaila T, Saari KM. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefes Arch Clin Exp Ophthalmol 2002; 240: 430-435.
- 2. Diggory P, Franks W. Medical treatment of glaucoma — a reappraisal of the risks. Br J Ophthalmol 1996; 80: 85-89.
- 3. Lewis PR, Phillips TG, Sassani JW. Topical therapies for glaucoma: what family physicians need to know. Am Fam Physician 1999; 59: 1871-1879. http://www.aafp.org/afp/990401ap/1871.html (accessed Aug 2008).
- 4. Goldberg I, Adena MA. Co-prescribing of topical and systemic beta-blockers in patients with glaucoma: a quality use of medicine issue in Australian practice. Clin Experiment Ophthalmol 2007; 35: 700-705.
- 5. Schuman JS. Effects of systemic β-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Ophthalmology 2000; 107: 1171-1177.
- 6. Han JA, Frishman WH, Wu Sun S, et al. Cardiovascular and respiratory considerations with pharmacotherapy of glaucoma and ocular hypertension. Cardiol Rev 2008; 16: 95-108.
- 7. Gottfredsdottir MS, Allingham RR, Shields MB. Physicians’ guide to interactions between glaucoma and systemic medications. J Glaucoma 1997; 6: 377-383.
- 8. O’Donoghue E. Beta blockers and the elderly with glaucoma: are we adding insult to injury? Br J Ophthalmol 1995; 79: 794-796.
- 9. Schweitzer I, Maguire K, Ng CH. A case of melancholic depression induced by β-blocker antiglaucoma agents. Med J Aust 2008; 189: 406-407.
- 10. Glynn RJ, Seddon JM, Krug JH Jr, et al. Falls in elderly patients with glaucoma. Arch Ophthalmol 1991; 109: 205-210.
- 11. Levy Y, Zadok D. Systemic side effects of ophthalmic drops. Clin Paediatr (Phila) 2004; 43: 99-101.
- 12. Weston BC. Migraine headache associated with latanoprost. Arch Ophthalmol 2001; 119: 300-301.
- 13. Fan DS, Ng JS, Lam DS. A prospective study on ocular hypertensive and antiinflammatory response to different dosages of fluoromethalone in children. Ophthalmology 2001; 108: 1973-1977.
- 14. Lancaster T, Swart AM, Jick H. Risk of serious haematological toxicity with use of chloramphenicol eye drops in a British general practice database. BMJ 1998; 316: 667.
- 15. Smith JR, Wesselingh S, Coster D. It is time to stop using topical chloramphenicol. Aust N Z J Ophthalmol 1997; 25: 83-88.
- 16. Lam RF, Lai JSM, Ng JSK, et al. Topical chloramphenicol for eye infections. Hong Kong Med J 2002; 8: 44-47.
- 17. Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv Ophthalmol 1993; 37: 435-456.
- 18. Hepsen IF, Yildirim Z, Yilmaz H, Kotuk M. Preventative effect of lacrimal occlusion on topical timolol-induced bronchoconstriction in asthmatics. Clin Experiment Ophthalmol 2004; 32: 597-602.
Ivan Goldberg has received educational grants from Alcon, Allergan, and Pfizer; honoraria from Alcon, Allergan, Pfizer, Merck and Ellex; and research support from Alcon, Allergan, Pfizer and Novartis.